Using 68Ga-DOTATATE PET/CT to diagnose soft tissue sarcomas
Clinical Feasibility and Potential Clinical Benefit of 68Ga-DOTATATE PET/CT Assessment of Soft Tissue Sarcomas for Potential Peptide Receptor Radionuclide Therapy
This study is testing a new type of imaging called 68Ga-DOTATATE PET/CT to see if it can help doctors better diagnose soft tissue sarcomas in patients.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ohio State University Comprehensive Cancer Center Academic / other |
| Drugs / interventions | radiation, chemotherapy |
| Locations | 1 site (Columbus, Ohio) |
| Trial ID | NCT06500065 on ClinicalTrials.gov |
What this trial studies
This trial evaluates the effectiveness of 68Ga-DOTATATE digital PET/CT imaging in diagnosing soft tissue sarcomas. The study aims to assess the feasibility and capability of this advanced imaging technique, which may enhance image quality and provide better detection of tumors. Patients will receive the radiotracer intravenously and undergo imaging to evaluate tumor characteristics and response to therapy. The trial also seeks to determine the safety of 68Ga-DOTATATE in this patient population.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older diagnosed with any stage of soft tissue sarcomas who are candidates for systemic therapies.
Not a fit: Patients with hypersensitivity to somatostatin, those who have received long-acting somatostatin analogs recently, or those unable to undergo the imaging due to claustrophobia or other medical conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate diagnoses and better treatment planning for patients with soft tissue sarcomas.
How similar studies have performed: While this specific approach is novel, similar imaging techniques have shown promise in enhancing diagnostic capabilities for various cancers.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients \>= 18 years of age * Patients diagnosed with any stage of soft tissue sarcomas candidates for systemic therapies * Patients with one standard of care PET/CT scan up to 30 days before enrollment at the Ohio State University facilities. Exclusion Criteria: * Hypersensitivity to somatostatin or similar peptides * Somatostatin long-acting analog in the past 6 months * Patients who are pregnant or lactating * Patients who are currently incarcerated * Patients with acute infections * Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.) * Patients exceeding the weight limitations of the scanner or are not able to enter the bore of the dPET/CT scanner due to body mass index (BMI)
Where this trial is running
Columbus, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio, United States (Recruiting)
Study contacts
- Principal investigator: Gabriel R Tinoco Suarez — Ohio State University Comprehensive Cancer Center
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.